Clinical Trial

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive disease (PD), while also have the choice to pursue with other drugs after discussing with their physicians.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-26.
Trial Details
NCT Number NCT07154368
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Non Small Cell Lung Cancer
Enrollment 207 participants
Start Date 2025-09-23
Primary Completion 2027-10-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-19